Gilead Sciences' (GILD +0.5%) once-daily Sofosbuvir drug met the goals of two Phase III studies...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead Sciences' (GILD +0.5%) once-daily Sofosbuvir drug met the goals of two Phase III studies in patients with chronic hepatitis C who have never been treated for it. In both cases, Sofosbuvir, in combination with other treatments, achieved meaningful response rates. (PR)